Clinical Trials
36 trialsNCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT05417594 2026-06-02
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT06717295 2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT04913337 2024-10-02
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
Phase 1/2 Active not recruiting
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT02498665 2023-11-14
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03561207 2023-03-24
3D-PREDICT
KIYATEC
Unknown
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT05476341 2022-07-27
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT01248949 2017-03-29
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00120939 2009-04-03
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
Phase 1 Completed
NCT00338026 2008-07-15
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
Thallion Pharmaceuticals
Phase 1 Completed